POZ Community Forums
Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: Jim Allen on May 13, 2023, 03:23:49 am
-
Very small study but good results for those with Multidrug-Resistant HIV.
POZ.com article https://www.poz.com/article/biktarvy-plus-pifeltro-option-people-multidrugresistant-hiv
In Short:
An all-oral regimen of Biktarvy plus Pifeltro maintained viral suppression in people with highly drug-resistant HIV who switched from an older combination regimen, according to a small study published in the journal AIDS.
The study included 20 men, almost all white, who had a median age of 65 years and had been living with HIV for a median of 37 years.
All participants in this open-label study switched from the Odefsey combination pill (rilpivirine/tenofovir alafenamide/emtricitabine) plus Tivicay (dolutegravir) to the Biktarvy coformulation (bictegravir/tenofovir alafenamide/emtricitabine) plus Pifeltro (doravirine).
The participants had documented resistance to protease inhibitors, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and/or NNRTIs but no known resistance to rilpivirine or doravirine and no K65R or T69 mutations.
At 48 weeks after the switch, 100% of participants still had a viral load below 50
.